The Form 4 filing, an SEC report of an insider's stock trades, was filed on October 13, 2026. It lists October 12, 2026, as the transaction date for Martine A. Rothblatt, United Therapeutics' chairperson and CEO.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-12 |
| Date of Latest Transaction | 2026-10-12 |
| Buy/Sell | sell |
| Transaction Count | 7 |
| Shares Transacted | 9,500 |
| Price | $550.70 |
| Total Transaction Value | $5,231,666.41 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-10-13 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale, reported with transaction code S. The reported activity covers seven transactions in United Therapeutics (UTHR) shares.
What was the average price of the transaction?
The average price was $550.70 per share for the reported sales. Separate prices for each of the seven transactions are not available in the details used for this report.
How did this transaction affect the insider's holdings?
Rothblatt sold 9,500 shares and reported owning 324,443 shares afterward. The shares sold made up 2.84% of the shares owned before the sale.
What's the total transaction value?
The total sale value was $5,231,666.41 across all seven reported transactions.
Are there any special circumstances around this transaction?
The transaction details include a Rule 10b5-1 reference. This points to a trading plan that sets instructions in advance. The plan text and filing footnotes are not available for this report, so it is unclear which trades the plan covers. The date the plan was set up and its trading schedule are also unknown.
For research purposes only; not investment advice.